Initial chemosensitivity is known concerning SCLC but relapse is almost systematic, especially at a metastatic stage. Brain metastasis are identified around 40 to 50% during the evolution of the disease. Concerning the efficacy of epirubicin combined with paclitaxel from the second-line treatment, data is lacking more particularly about specific response on brain metastasis. In this retrospective multicentric observational study in real life conditions, we try to evaluate systemic and specific cerebral efficacy and safety of a regimen combining epirubicin and paclitaxel in patients treated between 2010 and 2020 for a small cell lung carcinoma from the second-line treatment.
Study Type
OBSERVATIONAL
Enrollment
29
CHRU de Brest
Brest, France
Hôpital de Landerneau
Landerneau, France
CHIC
Quimper, France
Progression-free survival
Time from epirubicin-paclitaxel regimen initiation to disease progression (according to Response Evaluation Criteria In Solid Tumors v1.1) or death from any cause
Time frame: through study completion, an average of 1 year
Overall survival
Time from epirubicin-paclitaxel regimen initiation to death from any cause
Time frame: 1 year
Objective response rate
Complete response or partial response (according to Response Evaluation Criteria In Solid Tumors v1.1)
Time frame: 1 year
Disease control rate
Objective response rate and stable disease (according to Response Evaluation Criteria In Solid Tumors v1.1)
Time frame: 1 year
Intracranial control rate
Objective response rate and stable disease (according to Response Evaluation Criteria In Solid Tumors v1.1)
Time frame: 1 year
Toxicities
According to Common Toxicity Criteria for Adverse Events version 5.0.
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.